Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?

In Q2 2026, Eli Lilly reported revenue of $23.0 billion versus Bristol Myers Squibb’s $13.0 billion; Lilly’s revenue rose from $11.4 billion in Q3 2024, while BMS’s remained comparatively steady. Lilly said Mounjaro generated $9.9 billion in worldwide sales, up 91% year over year, and Zepbound had $4.9 billion in U.S. sales, up 44% to 46%; both companies raised full-year guidance. Lilly’s GLP-1 momentum is offset by product concentration and discounting risks, while BMS trades at about 9.4 times forward earnings versus nearly 25 times for Lilly; both are scheduled to report Q3 results on Oct. 29.

Analysis

The useful distinction is not simply growth versus stability, but what each revenue stream must prove next: Lilly needs to convert GLP-1 volume into durable, profitable growth despite concentration and price pressure; BMY needs to show newer products can offset erosion in established franchises. Lilly’s concentration creates asymmetric sensitivity to net pricing, supply availability, payer coverage, and competition from Novo Nordisk. If volume growth remains strong but net prices or product mix weaken, revenue could still rise while earnings conversion disappoints—an important risk at its higher valuation multiple. BMY’s lower multiple is not automatically a floor: a growth-portfolio share of sales matters only if those products sustain growth and replace losses from older drugs. The Nvidia collaboration and expanded approvals are not, by themselves, evidence of near-term financial uplift.

Oct. 29 earnings are the immediate catalyst; avoid treating the supplied quarterly series as a clean forecast without checking accounting basis, reported versus adjusted revenue, and consensus estimates. Over 1–3 months, watch Lilly’s demand, net-price commentary, supply capacity, and guidance, alongside BMY’s product-level growth and franchise erosion. Over 6–18 months, payer and policy pressure, competitive launches, and Lilly’s ability to broaden its revenue base could matter more than headline sales growth. Contrarian angle: the market may over-reward Lilly’s top-line acceleration before testing earnings durability, while underweighting BMY’s replacement-product potential—but BMY’s apparent value can become a value trap if erosion outruns growth. Thesis breaks if Lilly sustains guidance and pricing while broadening growth, or if BMY’s growth portfolio fails to offset declines.

Key Decisions for Investors

• Do not initiate a large pre-earnings pair trade solely from the reported revenue trend. Reconcile fiscal/calendar periods and reported versus adjusted figures, then compare Oct. 29 results with consensus.
• Consider a small, defined-risk relative-value position only after the print: long BMY versus short LLY if BMY’s growth products continue to offset legacy erosion and Lilly’s net pricing or guidance disappoints. Invalidate on BMY growth weakness or Lilly guidance/price resilience; size for earnings-gap risk.
• For LLY, track prescription volume alongside net price, supply, and payer access—not revenue alone. Sustained volume with stable pricing and broader product contribution would falsify the concentration-risk thesis; slowing demand or weaker guidance would strengthen it.
• For BMY, monitor product-level growth and declines in established franchises. Treat the Nvidia partnership and regulatory approvals as watch items, not near-term earnings catalysts, unless the company provides measurable commercial or R&D productivity evidence.